New horizons in target antigen selection in adoptive cell therapy of cancer

Wei Feng, Ren Xiubao

    Research output: Contribution to journalArticle


    Adoptive cell transfer (A CT) is a passive immunotherapy of cancer. Recently, researchers have observed that durable complete cancer regressions can be achieved in patients with metastatic melanoma after ACT, encouragingly suggesting a great potential for ACT in the treatment of cancer in clinical settings. This potential can be further enhanced when genetic modification of lymphocytes is perfomied. The key to the success of adoptive cell therapy is the identification of suitable immunologic targets on cancer cells that can be attacked by tumor infiltrating lymphocytes (TIL) or genetically modified lymphocytes without damaging nomial tissues. Differentiation antigens overexpressed on cancers, shared non-mutated antigens of cancers, and antigens from tumor stroma are not suitable targets of ACT due to their low level expres-sion in nomial tissues. On the contrary, antigens encoded by shared mutations, viral oncogenes, or unique driven muta-tions may serve as ideal targets of ACT. Further development of ACT will result from new adoptive cell immunotherapy strategies with lymphocytes that recognize mutated antigens, in particular those derived from gene products that are in-volved in carcinogenesis.

    Original languageEnglish (US)
    Pages (from-to)191-196
    Number of pages6
    JournalChinese Journal of Cancer Biotherapy
    Issue number2
    StatePublished - Apr 1 2015



    • Adoptive cell transfer (A CT)
    • Antigen
    • Mutation
    • Tumor

    ASJC Scopus subject areas

    • Molecular Medicine
    • Pharmacology
    • Cancer Research

    Cite this